LeukemiaTT115/VideoTARGET AUDIENCE OVERVIEW OF ACTIVITY By reviewing the available clinical trial data and relevant case scenarios, this initiative will provide insight into the gaps in medical knowledge and illuminate treatment ambiguities pertinent to the management of acute and chronic leukemias and MDS. To address these issues, this CME program brings together leading clinical investigators to provide biological insights into the recent therapeutic advances in the management of these cancers. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Jennifer R Brown, MD, PhD Advisory Committee: Celgene Corporation, Emergent BioSolutions Inc, Gilead Sciences Inc, Janssen Biotech Inc, MorphoSys, Pharmacyclics Inc, ProNAi Therapeutics Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Emergent BioSolutions Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, MorphoSys, Pharmacyclics Inc, ProNAi Therapeutics Inc, Roche Laboratories Inc. Hagop M Kantarjian, MD No real or apparent conflicts of interest to disclose. Charles A Schiffer, MD Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Novartis Pharmaceuticals Corporation, Takeda Oncology; Consulting Agreement: Celgene Corporation; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Takeda Oncology; Research Support: MedImmune Inc; Other Remunerated Activities: Pfizer Inc, Takeda Oncology. B Douglas Smith, MD Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc. David P Steensma, MD Advisory Committee: Amgen Inc, Celgene Corporation, Genoptix Inc. Wendy Stock, MD, MA Advisory Committee: Amgen Inc, Gilead Sciences Inc, Sigma-Tau Pharmaceuticals Inc. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation and Teva Oncology. Hardware/Software Requirements: Last review date: August 2015 |